This bill amends the Federal Food, Drug, and Cosmetic Act to revise the requirements for health care economic information that is provided to entities selecting drugs for coverage or reimbursement, such as formularies. The information must include a conspicuous and prominent statement describing the differences between the information and the labeling approved for the drug.
"Health care economic information" is an analysis that describes the economic consequences of the use of a drug. Such an analysis is no longer required to compare the use of the drug to another intervention or no intervention. An analysis that relates only to an indication for which the drug is not approved is not health care economic information.| Action Date | Type | Text | Source |
|---|---|---|---|
| 2015-05-22 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2015-05-19 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
| 2015-05-19 | IntroReferral | Introduced in House | Library of Congress |